Literature DB >> 15488609

HIV-infection of the central nervous system: the tightrope walk of innate immunity.

Cornelia Speth1, Manfred P Dierich, Sieghart Sopper.   

Abstract

Infection of the central nervous system (CNS) by HIV is a frequent and sometimes very early event in the course of HIV pathogenesis. Possible consequences are diverse symptoms of neurological dysfunction, but also the establishment of a lifelong latent viral reservoir in the brain. Whereas in the periphery innate and adaptive immunity are equal partners, the blood-brain barrier (BBB) with its restricted access of peripheral immune effectors shifts this balance in favour of the local innate immunity. Four main elements of cerebral innate immunity are discussed in the present article, including two cell types with immunological functions and two soluble immune systems: (1) the stimulation of microglial cells as the predominant brain-resident immune cell and the main local reservoir for the virus; (2) the reaction of astrocytes in response to viral infection; (3) the activation of the local complement system as important soluble immune cascade; and (4) the role of chemokines and cytokines which help to conduct and cross-link the interplay between the different immune elements. These components of the cerebral innate immunity do not act separately from each other but form a functional immunity network. A dual role of these components with both harmful and protective effects further enhances the complexity of the mutual interactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15488609     DOI: 10.1016/j.molimm.2004.06.018

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  36 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 3.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

Review 4.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

5.  Adenovirus RIDalphabeta complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression.

Authors:  Fernando Delgado-Lopez; Marshall S Horwitz
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia.

Authors:  Brian Giunta; Demian Obregon; Hauyan Hou; Jin Zeng; Nan Sun; Veljko Nikolic; Jared Ehrhart; Douglas Shytle; Francisco Fernandez; Jun Tan
Journal:  Brain Res       Date:  2006-10-31       Impact factor: 3.252

Review 7.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

8.  BAG3 protein regulates caspase-3 activation in HIV-1-infected human primary microglial cells.

Authors:  Alessandra Rosati; Kamel Khalili; Satish L Deshmane; Sujatha Radhakrishnan; Maria Pascale; M Caterina Turco; Liberato Marzullo
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

Review 9.  Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS.

Authors:  Leslie Crews; Margaret R Lentz; R Gilberto Gonzalez; Howard S Fox; Eliezer Masliah
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.